# NM_013280.5(FLRT1):c.288C>T (p.Ala96=)

https://sugi.bio/variant/flrt1-p-ala96

## Summary

**FLRT1 p.Ala96= (c.288C>T)** is classified **Benign** in FLRT1 (ClinVar, Multiple submitters, 2 submitters; last evaluated 2026-01-19). Common (popmax 67.9%, nfe) — too common for a highly-penetrant pathogenic allele; Associated with peripheral neuropathy.

**At a glance:** Benign · review: Multiple submitters · rsID rs614035 · 2 submitters · 1 linked condition · common (popmax 67.9%, nfe) — too common for a highly-penetrant pathogenic allele

> **Built without this gene's context.** ClinVar files this variant under an overlapping gene, so its own gene's record set does not contain it and this page is assembled from the variant alone. Gene constraint and dosage, protein structure, pathways, panels and related-variant links were not looked up — absent from this page, not from the data.

## For patients & families {#patients}

This is a change in the FLRT1 gene that is classified as benign — not considered disease-causing, submitted by 2 submitters, and is linked to peripheral neuropathy.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

|  |  |
| --- | --- |
| Clinical trials | 346 registered for this condition — see ClinicalTrials.gov |

**Support & next steps:** [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [FLRT1](https://sugi.bio/atlas/gene/FLRT1/) |
| Protein change (HGVS p.) | p.Ala96= |
| Coding change (HGVS c.) | c.288C>T |
| MANE Select transcript | [NM_013280](https://www.ncbi.nlm.nih.gov/nuccore/NM_013280) |
| dbSNP | [rs614035](https://www.ncbi.nlm.nih.gov/snp/rs614035/) |
| Variant type | single nucleotide variant |
| Location | chr11:64116555-64116555 (GRCh38) |
| ClinVar | [VCV1167055](https://www.ncbi.nlm.nih.gov/clinvar/variation/1167055/) |

**All HGVS expressions:** `NC_000011.10:g.64116555C>T`, `NC_000011.9:g.63884027C>T`, `NM_001384466.1:c.288C>T`, `NM_001411019.1:c.517+34684G>A`, `NM_001423967.1:c.204C>T`, `NM_013280.5:c.288C>T`, `NM_014067.4:c.517+34684G>A`

## Computational & population evidence {#evidence}

**Concordance:** Evidence sources **disagree** — common (popmax 67.9%, nfe) — too common for a highly-penetrant pathogenic allele.

- **Missense predictors (AlphaMissense/REVEL/SaProt) do not apply** to this variant type — they score amino-acid substitutions only. For non-missense variants the computational signal comes from conservation (below), not from a missing predictor score.
- Conservation: phyloP -10.265, GERP -4 — fast-evolving / accelerated position
- CADD: **PHRED 0.044**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- SpliceAI: **not looked up on this page** — it was served without the gene's SpliceAI index, so no lookup was made. This is a gap in this page, not in the data, and says nothing about whether a splicing effect is predicted.
- Population frequency (gnomAD v4.1): grpmax **67.9%** (nfe) · FAF95 67.8% · FAF99 67.7% · 801,007/1,179,916 in the highest group · 1,019,520/1,613,820 alleles overall — common (popmax 67.9%, nfe) — too common for a highly-penetrant pathogenic allele.

| Ancestry group | Allele frequency | 1 in |
| --- | --- | --- |
| Amish (not grpmax-eligible) | 75.5% | 1 |
| Finnish (not grpmax-eligible) | 71.6% | 1 |
| Ashkenazi Jewish (not grpmax-eligible) | 70.9% | 1 |
| European (non-Finnish) (grpmax) | 67.9% | 1 |
| Middle Eastern | 64.8% | 2 |
| Remaining individuals (not grpmax-eligible) | 61.4% | 2 |
| Admixed American | 52.7% | 2 |
| South Asian | 51.1% | 2 |
| East Asian | 30.9% | 3 |
| African / African-American | 22.2% | 4 |

Amish shows a higher raw frequency than the grpmax group. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and "Remaining individuals" — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Clinical significance {#significance}

**Benign** — review status Multiple submitters *(criteria provided, multiple submitters, no conflicts)*, last evaluated 2026-01-19.

**Submitter consensus:** unanimous (2/2 Benign).

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Breakthrough Genomics, Breakthrough Genomics | Benign | criteria provided, single submitter | not provided |  |
| Labcorp Genetics (formerly Invitae), Labcorp | Benign | criteria provided, single submitter | clinical testing | 2026-01-19 |

## Associated conditions {#conditions}

[peripheral neuropathy](https://sugi.bio/atlas/disease/peripheral-neuropathy/).

**Reported phenotype names (ClinVar):** Peripheral neuropathy, not provided, none provided, Neuropathy.

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-14); gnomAD v4.1 (Broad Institute, built 2026-10-06); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-10-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 1167055). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*